 Barbara Frederick
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 11 | 2020 | 561 | 1.240 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 132 | 0.700 |
Why?
| | Cetuximab | 2 | 2020 | 111 | 0.670 |
Why?
| | Phthalazines | 2 | 2020 | 63 | 0.660 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 53 | 0.630 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 423 | 0.580 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 441 | 0.580 |
Why?
| | DNA Repair | 2 | 2020 | 254 | 0.580 |
Why?
| | Piperazines | 2 | 2020 | 375 | 0.570 |
Why?
| | Quinazolines | 3 | 2007 | 266 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2014 | 640 | 0.480 |
Why?
| | ErbB Receptors | 5 | 2020 | 635 | 0.430 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2025 | 48 | 0.370 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2025 | 932 | 0.310 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 273 | 0.310 |
Why?
| | Mice, Nude | 7 | 2020 | 679 | 0.300 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2007 | 108 | 0.290 |
Why?
| | Cell Line, Tumor | 12 | 2025 | 3539 | 0.280 |
Why?
| | Piperidines | 2 | 2007 | 220 | 0.260 |
Why?
| | Smad4 Protein | 2 | 2020 | 34 | 0.240 |
Why?
| | Mesoderm | 1 | 2007 | 147 | 0.240 |
Why?
| | Protein Biosynthesis | 4 | 2025 | 451 | 0.230 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1264 | 0.220 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 285 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 238 | 0.200 |
Why?
| | Neoplasms | 4 | 2023 | 2900 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 168 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 881 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 1188 | 0.170 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 175 | 0.160 |
Why?
| | Epithelial Cells | 1 | 2007 | 1127 | 0.160 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 22 | 0.160 |
Why?
| | Proof of Concept Study | 1 | 2020 | 89 | 0.160 |
Why?
| | Apoptosis | 5 | 2025 | 2434 | 0.160 |
Why?
| | Clone Cells | 1 | 2020 | 263 | 0.160 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 158 | 0.160 |
Why?
| | Drug Synergism | 1 | 2020 | 354 | 0.150 |
Why?
| | Drosophila melanogaster | 2 | 2012 | 236 | 0.150 |
Why?
| | Prostatic Neoplasms | 3 | 2013 | 978 | 0.140 |
Why?
| | Cisplatin | 1 | 2020 | 344 | 0.140 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2207 | 0.140 |
Why?
| | Mice | 10 | 2025 | 18303 | 0.140 |
Why?
| | Radiation, Ionizing | 3 | 2012 | 86 | 0.130 |
Why?
| | Lung Neoplasms | 2 | 2008 | 2662 | 0.130 |
Why?
| | Animals | 15 | 2025 | 37952 | 0.120 |
Why?
| | DNA Damage | 3 | 2020 | 435 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1442 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 409 | 0.110 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 43 | 0.110 |
Why?
| | Stromal Cells | 1 | 2014 | 120 | 0.100 |
Why?
| | N-Glycosyl Hydrolases | 2 | 2004 | 6 | 0.100 |
Why?
| | Radiation Tolerance | 1 | 2014 | 103 | 0.100 |
Why?
| | Adherens Junctions | 1 | 2013 | 24 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 194 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2014 | 200 | 0.100 |
Why?
| | Plant Proteins | 2 | 2004 | 111 | 0.100 |
Why?
| | Signal Transduction | 6 | 2014 | 5208 | 0.090 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 17 | 0.090 |
Why?
| | Sulfones | 1 | 2013 | 127 | 0.090 |
Why?
| | Exosomes | 1 | 2013 | 104 | 0.090 |
Why?
| | Prostate | 1 | 2013 | 158 | 0.090 |
Why?
| | Metalloporphyrins | 1 | 2012 | 63 | 0.090 |
Why?
| | Glycine | 1 | 2013 | 186 | 0.090 |
Why?
| | Radiotherapy | 1 | 2012 | 204 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 38 | 0.080 |
Why?
| | Stilbenes | 1 | 2011 | 30 | 0.080 |
Why?
| | Maytansine | 1 | 2011 | 18 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4552 | 0.080 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2011 | 70 | 0.080 |
Why?
| | Paclitaxel | 1 | 2012 | 256 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1958 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 506 | 0.080 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 21 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 86 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 749 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 550 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2009 | 117 | 0.070 |
Why?
| | Up-Regulation | 2 | 2014 | 846 | 0.070 |
Why?
| | Humans | 20 | 2025 | 145140 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2025 | 2504 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2011 | 178 | 0.060 |
Why?
| | Receptors, LHRH | 2 | 2004 | 14 | 0.060 |
Why?
| | Glutathione | 1 | 2009 | 370 | 0.060 |
Why?
| | Cortactin | 1 | 2006 | 7 | 0.060 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2006 | 8 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2009 | 322 | 0.060 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2006 | 59 | 0.060 |
Why?
| | Hypoxia | 1 | 2013 | 1197 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 753 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 337 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 666 | 0.060 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 380 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 167 | 0.050 |
Why?
| | Immunotoxins | 1 | 2004 | 55 | 0.050 |
Why?
| | Cell Cycle | 2 | 2020 | 596 | 0.050 |
Why?
| | Female | 5 | 2020 | 78636 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2003 | 216 | 0.040 |
Why?
| | Drug Discovery | 1 | 2023 | 153 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 979 | 0.040 |
Why?
| | Carcinoma | 1 | 2003 | 224 | 0.040 |
Why?
| | Phosphorylation | 1 | 2025 | 1706 | 0.040 |
Why?
| | Mutation | 4 | 2013 | 4071 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | HCT116 Cells | 2 | 2011 | 76 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 140 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 288 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 886 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 239 | 0.030 |
Why?
| | Cell Line | 1 | 2023 | 2821 | 0.030 |
Why?
| | Transfection | 2 | 2011 | 926 | 0.030 |
Why?
| | Veratrum Alkaloids | 1 | 2014 | 20 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3410 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1100 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | Ribosome Inactivating Proteins, Type 1 | 2 | 2004 | 3 | 0.030 |
Why?
| | Tetraspanins | 1 | 2013 | 18 | 0.030 |
Why?
| | Annexin A2 | 1 | 2013 | 15 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 631 | 0.030 |
Why?
| | Metalloproteases | 1 | 2013 | 42 | 0.030 |
Why?
| | CHO Cells | 2 | 2004 | 169 | 0.020 |
Why?
| | Cricetinae | 2 | 2004 | 302 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 247 | 0.020 |
Why?
| | Models, Biological | 2 | 2012 | 1763 | 0.020 |
Why?
| | Blotting, Western | 2 | 2007 | 1177 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2013 | 139 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1146 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 247 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 108 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2013 | 115 | 0.020 |
Why?
| | Penis | 1 | 2012 | 33 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 219 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 38 | 0.020 |
Why?
| | Testis | 1 | 2012 | 162 | 0.020 |
Why?
| | Comet Assay | 1 | 2011 | 14 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 382 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 454 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4310 | 0.020 |
Why?
| | BRCA1 Protein | 1 | 2011 | 82 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 94 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 295 | 0.020 |
Why?
| | Glioma | 1 | 2015 | 429 | 0.020 |
Why?
| | Spindle Apparatus | 1 | 2011 | 95 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4142 | 0.020 |
Why?
| | Larva | 1 | 2011 | 240 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 193 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.020 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 9 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 382 | 0.020 |
Why?
| | Cytoprotection | 1 | 2009 | 56 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 629 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 959 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 343 | 0.020 |
Why?
| | Proteome | 1 | 2013 | 512 | 0.020 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2008 | 10 | 0.020 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2008 | 10 | 0.020 |
Why?
| | GRB2 Adaptor Protein | 1 | 2008 | 12 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 383 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 257 | 0.020 |
Why?
| | Luciferases | 1 | 2008 | 152 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 431 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2009 | 189 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1371 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 277 | 0.020 |
Why?
| | Skin | 1 | 2012 | 753 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1713 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 591 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 532 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2524 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 762 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 246 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1731 | 0.010 |
Why?
| | Gene Amplification | 1 | 2006 | 118 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1328 | 0.010 |
Why?
| | Histones | 1 | 2011 | 665 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 323 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 425 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2006 | 504 | 0.010 |
Why?
| | Colony-Forming Units Assay | 1 | 2004 | 95 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1261 | 0.010 |
Why?
| | Actins | 1 | 2006 | 424 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2003 | 34 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5582 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2004 | 149 | 0.010 |
Why?
| | Male | 4 | 2013 | 72664 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1351 | 0.010 |
Why?
| | Drug Combinations | 1 | 2003 | 396 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 946 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 707 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2003 | 1109 | 0.010 |
Why?
| | Protein Binding | 1 | 2004 | 2235 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2003 | 2803 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 11741 | 0.010 |
Why?
|
|
Frederick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|